Mazindol

Mazindol

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	Oral
ATC code	A08AA05 (WHO)
Legal status
Legal status	CA: Schedule IV DE: Anlage II (Prohibited) US: Schedule IV Schedule IV (International)
Pharmacokinetic data
Bioavailability	93%
Metabolism	Hepatic
Biological half-life	10-13 hours
Excretion	Renal
Identifiers
IUPAC name (±)-5-(4-chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol
CAS Number	22232-71-9 Y
PubChem CID	4020
IUPHAR/BPS	4797
DrugBank	DB00579 Y
ChemSpider	3880 Y
UNII	C56709M5NH
KEGG	D00367 Y
ChEMBL	CHEMBL781 Y
ECHA InfoCard	100.040.764
Chemical and physical data
Formula	C16H13ClN2O
Molar mass	284.74 g/mol
3D model (Jmol)	Interactive image
Chirality	Racemic mixture
SMILES ClC1=CC=C(C2(C3=CC=CC=C3C4=NCCN42)O)C=C1
InChI InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2 Y Key:ZPXSCAKFGYXMGA-UHFFFAOYSA-N Y

Mazindol (Mazanor, Sanorex) is a stimulant drug of the tetracyclic chemical class which is used as an anorectic. It was developed by Sandoz-Wander in the 1960s.

Mazindol is used in short-term (i.e., a few weeks) treatment of exogenous obesity, in combination with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m²), or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or kghyperlipidemia. Mazindol is not currently available as a commercially marketed and FDA regulated prescription agent for the treatment of obesity.

Mazindol is a sympathomimetic amine, which is similar to amphetamine. It stimulates the central nervous system, which increases heart rate and blood pressure, and decreases appetite. Sympathomimetic anoretics (appetite suppressants) are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks of treatment. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.

Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Like other sympathomimetic appetite suppressants, mazindol is thought to act as a reuptake inhibitor of norepinephrine. In addition, it inhibits dopamine and serotonin reuptake. The recommended dosage is 2 mg per day for 90 days in patients 40 kg overweight and under; 4 mg a day in patients more than 50 kg overweight; separated into two doses separated by a 12-hour window between each 2 mg dose.